SRSandra S. Richter

Sandra S. Richter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandra S. Richter has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of BD Phoenix AP Workflow with Vitek 2

    by Alan D. Junkins, Sophie S. Arbefeville, Wanita J. Howard, Sandra S. Richter

    The BD Phoenix AP instrument reduced the manual setup time for the Phoenix system by 50%. For batches of 14 organisms, the average manual manipulation time per isolate was 89.5 s for BD Phoenix by the use of the AP instrument and 101 s for Vitek 2 ( P < 0.001).


  • BD Phoenix and Vitek 2 Detection of mecA -Mediated Resistance in Staphylococcus aureus with Cefoxitin

    by Alan D. Junkins, Shawn R. Lockhart, Kristopher P. Heilmann, Cassie L. Dohrn, Diana L. Von Stein, Patricia L. Winokur, Gary V. Doern, Sandra S. Richter

    The BD Phoenix (BD Diagnostics, Sparks, MD) and Vitek 2 (bioMérieux, Durham, NC) automated susceptibility testing systems have implemented the use of cefoxitin to enhance the detection of methicillin (meticillin)-resistant Staphylococcus aureus (MRSA). To assess the impact of this change, 620 clinically significant S. aureus isolates were tested in parallel on Phoenix PMIC/ID-102 panels and Vitek 2 AST-GP66 cards. The results for oxacillin and cefoxitin generated by the automated systems were compared to those generated by two reference methods: mecA gene detection and MICs of oxacillin previously determined by broth microdilution according to CLSI guidelines. Testing of isolates with discordant results was repeated to attain a majority or consensus final result. There was 100% final agreement between the results of the two reference methods. For the 448 MRSA and 172 methicillin-susceptible S . aureus isolates tested, the rates of categorical agreement of the results obtained with the automated systems with those obtained by the reference methods were 99.8% for the Phoenix panels and 99.7% for the Vitek 2 cards. A single very major error occurred on each instrument (0.2%) with different MRSA isolates. The only major error was attributed to the Vitek 2 system overcalling oxacillin resistance. In 16 instances (9 on the Phoenix system, 7 on the Vitek 2 system), an oxacillin MIC in the susceptible range was correctly changed to resistant by the expert system on the basis of the cefoxitin result. The inclusion of cefoxitin in the Phoenix and Vitek 2 panels has optimized the detection of MRSA by both systems.


  • Open Access

    Changing Epidemiology of Antimicrobial‐ResistantStreptococcus pneumoniaein the United States, 2004–2005

    by Sandra S. Richter, Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Susan E. Beekmann, Gary V. Doern

    Background. The impact of pediatric 7-valent pneumococcal conjugate vaccination (PCV-7) on the population of Streptococcus pneumoniae in the United S


  • Open Access

    Increasing telithromycin resistance among Streptococcus pyogenes in Europe

    by Sandra S. Richter, Kristopher P. Heilmann, Cassie L. Dohrn, Susan E. Beekmann, Fathollah Riahi, Juan Garcia-De-Lomas, Matus Ferech, Herman Goossens, Gary V. Doern

    To assess changes in macrolide and ketolide resistance among Streptococcus pyogenes in Europe and to examine the relationship of resistance to antimicrobial usage. Clinical S. pyogenes isolates were collected from Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, UK, Croatia, Hungary, Poland, Slovak Republic and Slovenia during 2002–03 (n = 2165) and 2004–05 (n = 2333). Resistance to telithromycin (MIC ≥2) and erythromycin (MIC ≥0.5) was determined by CLSI broth microdilution. Changes in resistance over time and the relationship of resistance to antimicrobial use (European Surveillance of Antimicrobial Consumption data) were assessed. Telithromycin-resistant isolates were characterized by PFGE to determine genetic relatedness and by PCR to detect mef(A), erm(A) and erm(B). The erythromycin resistance rate during 2004–05 (11.6%) was similar to 2002–03 (10.4%). The proportion of macrolide-resistant isolates with the constitutive MLSB phenotype increased from 29.3% (2002–03) to 45.7% (2004–05). Telithromycin resistance increased from 1.8% in 2002–03 to 5.2% in 2004–05. For Western Europe, associations of telithromycin and erythromycin resistance, respectively, were found with azithromycin use (R2 = 0.52 and 0.60), clarithromycin use (R2 = 0.76 and 0.85) and total macrolide/lincosamide use (R2 = 0.75 and 0.69). For Eastern Europe, associations of antimicrobial use with resistance were not apparent. The 162 telithromycin-resistant isolates comprised 42 PFGE patterns with 68.5% in eight major PFGE groups. The erm(B) gene was detected in 155 of the 162 telithromycin-resistant isolates. Significant increases in telithromycin resistance occurred from 2002–03 to 2004–05 in Europe. Macrolide use appears to be a factor in the emergence of ketolide resistance among S. pyogenes in Western Europe.


  • Multicenter Evaluation of the BD Phoenix Automated Microbiology System for Antimicrobial Susceptibility Testing of Streptococcus Species

    by Sandra S. Richter, Wanita J. Howard, Melvin P. Weinstein, David A. Bruckner, Janet F. Hindler, Michael Saubolle, Gary V. Doern

    This multicenter study evaluated the BD Phoenix Automated Microbiology System STREP panel (BD Diagnostic Systems). Antimicrobial susceptibility testing (AST) with 13 agents was performed on 2,013 streptococci (938 Streptococcus pneumoniae isolates; 396 group B streptococci [GBS]; 369 viridans group streptococci [VGS]; 290 beta-hemolytic streptococcus groups A, C, and G; and 20 other streptococci) with the Phoenix system and a broth microdilution reference method. Clinical and challenge isolates were tested against cefepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin. Clinical isolates with major errors or very major errors (VMEs) were retested in duplicate by both methods. The final results for clinical isolates showed the following trends. For all of the organism-antimicrobial agent combinations tested, categorical agreement (CA) was 92 to 100%, with one exception—VGS-PEN (87% CA; all errors were minor). For S. pneumoniae , there was one major error with CLI (0.1%) and one or two VMEs with CTX (4%), CTR (4.5%), ERY (0.9%), and TET (0.7%). For groups A, C, and G, the CA was 97 to 100% and the only VMEs were resolved by additional reference laboratory testing. For GBS, there was only one VME (TET, 0.3%) and D-zone testing of 23 isolates with CLI major errors (one isolate unavailable) revealed inducible CLI resistance. For VGS, the major error rates were 0 to 3% and VMEs occurred with seven agents (3.5 to 7.1%). The mean times required for organism groups to generate results ranged from 8.4 to 9.4 h. The Phoenix system provided reliable and rapid AST results for most of the organism-antimicrobial agent combinations tested.


  • Open Access

    Macrolide-Resistant Streptococcus pyogenes in the United States, 2002-2003

    by Sandra S. Richter, Kristopher P. Heilmann, Susan E. Beekmann, Norma J. Miller, Ashley L. Miller, Cassie L. Rice, Christopher D. Doern, Sean D. Reid, Gary V. Doern

    Background. Increased levels of macrolide-resistant Streptococcus pyogenes in focal regions of the United States have been reported. The purpose of t


  • Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases

    by Sandra S. Richter, Rudolph P. Galask, Shawn A. Messer, Richard J. Hollis, Daniel J. Diekema, Michael A. Pfaller

    There are limited data regarding the antifungal susceptibility of yeast causing vulvovaginal candidiasis, since cultures are rarely performed. Susceptibility testing was performed on vaginal yeast isolates collected from January 1998 to March 2001 from 429 patients with suspected vulvovaginal candidiasis. The charts of 84 patients with multiple positive cultures were reviewed. The 593 yeast isolates were Candida albicans ( n = 420), Candida glabrata ( n = 112), Candida parapsilosis ( n = 30), Candida krusei ( n = 12), Saccharomyces cerevisiae ( n = 9), Candida tropicalis ( n = 8), Candida lusitaniae ( n = 1), and Trichosporon sp. ( n = 1). Multiple species suggesting mixed infection were isolated from 27 cultures. Resistance to fluconazole and flucytosine was observed infrequently (3.7% and 3.0%); 16.2% of isolates were resistant to itraconazole (MIC ≥ 1 μg/ml). The four imidazoles (econazole, clotrimazole, miconazole, and ketoconazole) were active: 94.3 to 98.5% were susceptible at ≤1 μg/ml. Among different species, elevated fluconazole MICs (≥16 μg/ml) were only observed in C. glabrata (15.2% resistant [R], 51.8% susceptible-dose dependent [S-DD]), C. parapsilosis (3.3% S-DD), S. cerevisiae (11.1% S-DD), and C. krusei (50% S-DD, 41.7% R, considered intrinsically fluconazole resistant). Resistance to itraconazole was observed among C. glabrata (74.1%), C. krusei (58.3%), S. cerevisiae (55.6%), and C. parapsilosis (3.4%). Among 84 patients with recurrent episodes, non-albicans species were more common (42% versus 20%). A ≥4-fold rise in fluconazole MIC was observed in only one patient with C. parapsilosis . These results support the use of azoles for empirical therapy of uncomplicated candidal vulvovaginitis. Recurrent episodes are more often caused by non-albicans species, for which azole agents are less likely to be effective.


  • Open Access

    The Molecular Epidemiology of Streptococcus pneumoniae with Quinolone Resistance Mutations

    by S. S. Richter, K. P. Heilmann, S. E. Beekmann, N. J. Miller, C. L. Rice, G. V. Doern

    Background. The purpose of this study was to determine the prevalence of fluoroquinolone resistance and quinolone resistance—determining region (QRDR) mutations among Streptococcus pneumoniae isolates in the United States during the period of 2001–2002. A second objective was to examine the genetic relatedness of pneumococcal isolates with parC and/or gyrA mutations during the period of 1994–2002.


  • Open Access

    The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species

    by S. S. Richter, D. E. Kealey, C. T. Murray, K. P. Heilmann, G. V. Doern

    Objective: The purpose of this study was to examine the in vitro activity of daptomycin using an optimal calcium (Ca2+) concentration (50 mg/L) against a diverse collection of enterococcal and Staphylococcus aureus clinical isolates, including glycopeptide-resistant enterococci (GRE) and methicillin-resistant S. aureus (MRSA). Methods: The activity of daptomycin was compared with the activities of seven other agents against 1483 enterococcal and S. aureus clinical isolates, including 303 GRE and 193 methicillin-resistant S. aureus (MRSA) strains. Susceptibility testing was performed by the NCCLS broth microdilution method, with one exception: Mueller–Hinton (MH) broth was supplemented to a physiological level of 50 mg/L Ca2+ when testing daptomycin. Daptomycin zone diameters were determined by disc diffusion with MH agar plates containing Ca2+ 50 mg/L. Results: All staphylococcal isolates tested, and the majority of enterococcal isolates (96.5%), would be considered susceptible to daptomycin if the breakpoint previously proposed of ≤2 mg/L was applied. The activity of daptomycin against MRSA and methicillin-susceptible S. aureus was essentially equal. Daptomycin also had similar activity against GRE and glycopeptide-susceptible enterococci. Every S. aureus isolate had a daptomycin zone diameter ≥20 mm, and all of the enterococcal isolates had daptomycin zone diameters ≥17 mm. Conclusions: Overall, daptomycin showed potent activity against S. aureus and enterococcal isolates, comparable to quinupristin–dalfopristin and linezolid.


  • Open Access

    Fluoroquinolone Resistance inStreptococcus pyogenes

    by Sandra S. Richter, Daniel J. Diekema, Kris P. Heilmann, Laurel S. Almer, Virginia D. Shortridge, Rod Zeitler, Robert K. Flamm, Gary V. Doern

    Streptococcus pyogenes isolated from blood and urine samples obtained from a 78-year-old woman was tested for susceptibility, and fluoroquinolone res